A Phase 4 interventional study of Ropivacaine in Thoracic Outlet Syndrome, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-14.
Sponsored by Mayo Clinic · Phase 4, Interventional, and Supportive care
This research is being done to evaluate the effects of receiving only a paravertebral block prior to first rib resection procedure versus receiving the block both pre and post procedure.
33 studies on the registry are indexed under Thoracic Outlet Syndrome; 11 are open to participants now.
This study's planned enrollment of 50 is close to the median of 50 across 17 interventional studies indexed under Thoracic Outlet Syndrome.
Browse Thoracic Outlet Syndrome studies →Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- All Thoracic Outlet Syndrome patients scheduled for first rib resection surgery.
Exclusion Criteria:
Subjects will receive a preoperative paravertebral block only
Drug: Ropivacaine
Subjects will receive one paravertebral block, administered preoperatively and one paravertebral block, administered on postoperative day 1
Drug: Ropivacaine
0.5% 3-4 mL per level, with levels T1 and T2 will be used as the block injectate
Change in pain level
Measured using the pain visual analog scale (VAS). The VAS line will be 100 mm long with each end marked with "no pain" on the left, and "worst possible pain" on the right; participant identify their pain level by indicating a point on the line between each end and this point is measured from the "No pain" end, and the number of millimeters is reported as the pain score.
Time frame: Time of discharge (approximately 1 day), day 1 post-op, day 3 post-op, day 7 post-op, and day 14 post-op
Change in quality of life
Measured using the Short Form (SF-36) Health Survey; The SF-36 Health Survey is a 36-item, participant-reported survey that measures patient health and disability. Possible scores range from 0 to 100, with 0 indicating maximum disability, and 100 indicating no disability
Time frame: Time of discharge (approximately 1 day), day 1 post-op, day 3 post-op, day 7 post-op, and day 14 post-op
Length of stay
Number of hours subjects are in the hospital following their surgical procedure
Time frame: Approximately 1 day
Plan to share: No
Started Oct 2022 (actual). Primary completion is estimated for Aug 2027, 58 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine